Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...
The internet claims that there is, and that it's called Windows 11 Government Edition, but is that really true? Read more: Major PC Brands Ranked Worst To Best The broader tech community became ...
Awardees will receive a $1,500 stipend to cover ACS Fall Meeting expenses. They will present their research at a Women Chemists Committee (WCC)/Merck half-day symposium and be recognized at the Awards ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...
Jefferies analyst Akash Tewari estimates that Winrevair could eventually peak with $11 billion in annual sales. Despite the ...
a TGF-beta-targeting PAH drug Merck acquired via its $11.5 billion takeover of Acceleron Pharma last year. Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck ...
Timed to the 50th anniversary of NASA’s celebrated Apollo 11 mission, APOLLO 11: First Steps Edition is a thrilling cinematic experience that showcases the real-life moments of humankind’s first steps ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first ...
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled ...
It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback